Qualigen Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
FFR$0.89+14.0%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Balance Sheets
| (Unaudited) | ||
|---|---|---|
| September 30, | December 31, | |
| 2025 | 2024 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $38,777,166 | $1,174,608 |
| Prepaid expenses and other current assets | 343,091 | 1,499,219 |
| Short-term notes receivable, net of allowance for credit losses of $261,000 at September 30, 2025 and $360,000 at December 31, 2024 | 4,348,107 | 2,010,692 |
| Total current assets | 43,468,364 | 4,684,519 |
| Other assets | 2,000 | 2,000 |
| Total Assets | $43,470,364 | $4,686,519 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities | ||
| Accounts payable | $1,282,224 | $1,568,065 |
| Accrued expenses and other current liabilities | 41,896 | 170,243 |
| Warrant liabilities | 362,323 | 269,175 |
| Convertible debt | 339,736 | — |
| Promissory notes | 2,897,107 | — |
| Total current liabilities | 4,923,286 | 2,007,483 |
| Commitments and Contingencies (Note 10) | - | - |
| Stockholders’ Equity (Deficit) | ||
| Preferred stock, $0.001 par value; 15,000,000 shares authorized; 45,044 and 6,256 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | $36,100,334 | $5,716,400 |
| Common stock, $0.001 par value; 225,000,000 shares authorized; 3,056,822 and 736,431 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 67,734 | 65,314 |
| Additional paid-in capital | 131,809,991 | 119,958,897 |
| Accumulated deficit | (129,430,981) | (123,061,575) |
| Total Stockholders’ Equity (Deficit) | 38,547,078 | 2,679,036 |
| Total Liabilities & Stockholders’ Equity (Deficit) | $43,470,364 | $4,686,519 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.